The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002001
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To evaluate the immunologic effects of zidovudine and ddI or ddC. To evaluate combined administration of zidovudine and ddI or ddC for clinical efficacy. To evaluate the safety and the tolerance of the coadministration of zidovudine and ddI or ddC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
San Juan Veterans Administration Med Ctr
🇵🇷San Juan, Puerto Rico
Georgetown Univ Med Ctr / Main Hosp 4
🇺🇸Washington, District of Columbia, United States
Univ of Colorado Health Sciences Ctr
🇺🇸Denver, Colorado, United States
Saint Vincent's Hosp Med Centre
🇦🇺Darlinghurst, Australia
Vanderbilt School of Medicine
🇺🇸Nashville, Tennessee, United States